The number of comorbidities a patient has can increase the patients risk of polypharmacy. In a study of 1.4 million patients in Scotland, the researchers examined data to view pharmacy data in comparison to left ventricular systolic dysfunction (LVSD) and comorbidities. They found that patients with LVSD had higher rates of comorbidity and polypharmacy. The LVSD group had a greater rate of repeat prescriptions. The initial data was reviewed again using only the number of comorbidities and revealed that poly-pharmacy was actually tied directly to the number of comorbidities rather than the diagnosis of LSVD. This suggests that a more watchful eye should be kept on these patients to reduce the risk of polypharmacy (Baron-Franco et al., 2017).
I NEED YOU TO COMMENT FROM THIS POST, 150 WORDS NEEDED AND A REFRENCE PLEASE